Moderna’s research shows that those who vaccinated later had fewer success cases
Moderna Inc. has released a set of data suggesting that its COVID-19 vaccine is effective in preventing deaths from serious health issues or “anxiety forms,” but acknowledging that efficacy over time decreases, such that those who received the vaccine last year are twice more likely to contract a successful case of the coronavirus disease.
According to the data, which Modern Released Wednesday, a “study shows a reduced risk of breakthrough infection in participants who were vaccinated last year (13 months after the first dose) compared to participants who were vaccinated recently (8 months after the first dose). was vaccinated.”
COVID-19 kills Americans at a rate of 1 in 500, shows data
A modern trial conducted over the summer, called the Phase 3 COVE study, revealed that “88 successful cases of COVID-19 were reported in the recently vaccinated group (per year) compared with 162 cases in the group vaccinated last year. 49.0 cases per 1000 person-years) (77.1 cases per 1000 person-years).”
In both groups, Moderna highlighted that “only 19 serious cases were observed.” Whereas there was a “numerical trend towards a lower rate of severe cases in the recently vaccinated groups”. Moderna stressed that the number of cases was so small that the trend was “not significant”.
The research found that those who were vaccinated earlier had a 50% higher rate of symptomatic success cases during the months of July and August than those who received subsequent vaccinations.
In a statement released with the data, Moderna CEO Stephen Bunsell stressed that the data “supports the need for booster shots.”
“The growing body of data on the effectiveness of the modern COVID-19 vaccine holds promise in looking at clinical and real-world evidence,” said Bansel. said of unpublished analysis. “The increased risk of breakthrough infection in COVE study participants who were vaccinated last year shows the effect of recent weakened immunity and supports the need for boosters to maintain high levels of protection.
Moderna has also requested authorization from the US Food and Drug Administration for a third-dose booster shot, which would be half the dose of its current vaccine.